Journal of Pharmaceutical Sciences, Год журнала: 2024, Номер unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Archives of Dermatological Research, Год журнала: 2025, Номер 317(1)
Опубликована: Фев. 19, 2025
Язык: Английский
Процитировано
0
International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 142136 - 142136
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
BioNanoScience, Год журнала: 2025, Номер 15(2)
Опубликована: Март 22, 2025
Язык: Английский
Процитировано
0
Frontiers in Bioscience-Landmark, Год журнала: 2025, Номер 30(3)
Опубликована: Март 20, 2025
Allergic disorders rising in prevalence globally, affecting a substantial proportion of individuals industrialized nations. The imbalance the immune system, characterized by elevated allergen-specific T helper 2 (Th2) cells and immunoglobulin E (IgE) antibodies, is key factor allergy development. Allergen-specific immunotherapy (AIT) only treatment capable alleviating allergic symptoms, preventing new sensitizations, reducing asthma risk rhinitis patients. Traditional AIT, however, faces challenges such as frequent administration, adverse effects, inconsistent patient outcomes. Nanoparticle-based approaches have emerged promising strategy to enhance AIT. This review explores utilization nanoparticles highlighting their ability interact with system improve therapeutic Various types nanoparticles, including polyesters, polysaccharide polymers, liposomes, protamine-based (NPs), polyanhydrides, been employed adjuvants or carriers AIT’s efficacy safety. Nanoparticles offer advantages allergen protection, improved response modulation, targeted cell delivery, reduced side effects. provides an overview current landscape nanoparticle-based immunotherapy, discussing its potential revolutionize compared traditional immunotherapy.
Язык: Английский
Процитировано
0
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Год журнала: 2025, Номер unknown
Опубликована: Апрель 2, 2025
One of the most potent therapeutic and diagnostic agents in contemporary medicine is monoclonal antibody (mAb). mAbs can perform a variety tasks breast cancer (BC), including identifying delivering medications to targets, preventing cell development, suppressing immune system inhibitors directly attacking cells. are one effective options, particularly for HER2, but they have not been well studied their use treating other forms BC, triple negative tumors. Bispecific trispecific created new opportunities more targeted specific efficacy, which has positive impact on viability antigen specificity. They versatile than treatment, emerging as popular option BC. However, limit treatment due certain adverse effects, fever, shaking, exhaustion, headache, nausea, vomiting, rashes, bleeding, difficulty breathing. To examine current prospective future capacities with regard detection present review highlights advantages disadvantages mAb approach.
Язык: Английский
Процитировано
0
IntechOpen eBooks, Год журнала: 2025, Номер unknown
Опубликована: Апрель 15, 2025
Antimicrobial resistance has created an urgent need for innovative therapeutic strategies beyond conventional antibiotics. Nanotechnology offers a groundbreaking approach to addressing this challenge by providing versatile tools targeted antimicrobial action. This chapter explores the application of nanomaterials in combating multidrug-resistant pathogens. Emphasis is placed on their mechanisms action, such as biofilm disruption, precision drug delivery, and enhancement efficacy. also discusses recent advancements nano-engineered systems pathogen targeting, well role overcoming mechanisms. By shedding light potential limitations nanotechnology therapy, aims present transformative ongoing battle against superbugs.
Язык: Английский
Процитировано
0
Journal of Pharmaceutical Sciences, Год журнала: 2024, Номер unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
0